Month: January 2023

BETHESDA, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) — Eagle Bancorp, Inc., (the “Company”) (NASDAQ: EGBN), the parent company of EagleBank, today announced that it will host a teleconference call for the financial community on January 19, 2023 at 10:00 a.m. (EST) to discuss its fourth quarter and year end 2022 financial results. Those results will be released after the close of business on January 18, 2023. Interested parties will need to register at the below-noted URL in order to listen and participate in the call. Once a participant registers with a valid email, they will receive a dial-in phone number and unique PIN number which will be needed to access the call.   The call will also be available live via webcast on the Company’s website, which is www.EagleBankCorp.com. A replay of the call will be available on the Company’s website...

PITTSBURGH, Jan. 04, 2023 (GLOBE NEWSWIRE) — Coherent Corp. (Nasdaq: COHR), a global leader in materials, networking, and lasers, announced today that the company will present at the following upcoming investor conference:25th Annual Needham Growth ConferenceDate:     Thursday, Jan. 12, 2023Time:   10:15 a.m. ET     ParticipantMary Jane Raymond, Chief Financial Officer     A real-time audio webcast of the presentation can be accessed via the Investor Relations section of the Coherent website at https://www.coherent.com/company/investor-relations/financial-webcasts. A replay of the webcast will be available on the company’s website following the conclusion of the event. About Coherent Coherent empowers market innovators to define the future through breakthrough technologies, from materials to systems. We deliver...

TEL AVIV, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, will announce its fourth quarter and full year 2022 financial results on Wednesday, February 8, 2023. Conference Call DetailsRadware management will host a call on Wednesday, February 8, 2023, at 8:30 a.m. EST to discuss its fourth quarter and full year 2022 results and outlook for the first quarter of 2023. Participants are advised to join the call approximately 15 minutes before the start time. US: 1-888-510-2008 (toll free) International: 1-646-960-0306Conference ID: 1864701 In addition, the call will be webcast live on the Company’s website at http://www.radware.com/ir/investor-events/. A replay of the call will be available for two days, starting two hours after the end...

Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency Applied Therapeutics will receive milestone payments of over €130 million and 20% royalty payments on net sales in Europe Deal strengthens Applied Therapeutics’ capital position and extends cash runway through key milestonesNEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a partnership with Advanz Pharma, a pharmaceutical company with a strategic focus on commercialization of specialty, hospital, and rare disease medicines, for commercialization...

NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s chief executive officer and president, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 12:45 PM ET. The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the webcast will be available for 30 days. About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare...

RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose tested Across all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates were 32% and 40%, respectively. Similar results were observed at the expected Phase 3 dose At the expected Phase 3 dose, among patients who were positive for a biomarker that was prospectively defined in TUSCANY-2, clinical remission and endoscopic improvement rates were 40% and 56%, respectively. Approximately 60% of patients were identified as positive for this biomarker At the expected Phase 3 dose, among patients who had been previously treated with biologics and who were biomarker positive, clinical remission and endoscopic improvement rates were 41% and 56%, respectively Across all doses and patient groups, RVT-3101 was well tolerated...

HMS Industrial Networks AB, a wholly owned subsidiary of HMS Networks AB (publ), has today acquired an additional 20% of all shares in Owasys Advanced Wireless Devices S.L. The acquisition will strengthen the collaboration between Owasys and HMS further and brings HMS’s ownership to 80% of the shares in Owasys. Owasys is already fully consolidated and will consequently have no impact on HMS’s sales and earnings per share in 2023. For more information, please contact:Staffan Dahlström, CEO HMS Networks AB, +46 (0)35 17 29 01Joakim Nideborn, CFO HMS Networks AB, +46 (0)35 710 6983 HMS Networks AB (publ) is a market-leading provider of solutions in industrial information and communication technology (Industrial ICT). HMS develops and manufactures products under the Anybus®, Ewon®, Intesis® and Ixxat® brands. Development takes place at the...

Wednesday, January 4, 2023   Dear Shareholders & Investors, I thought I would share with you my thoughts for what I think 2023 holds for our company.   The last days of 2022 are a good harbinger for the future: We concluded four contracts at rate levels of about USD 40,000 to USD 50,000 per day ranging between 30 days to 50 days each. As we have seen in the past, political uncertainty creates demand for the transport of oil. As a consequence of Russia’s invasion of Ukraine and the West’s strong reaction, energy security is of paramount concern.  Oil will have to be sourced from further away than in the past, creating longer voyages. Uncertain times also encourages hoarding among some buyers, adding to demand for oil and for the NAT tankers. I also see a longer-term trend, and that is the increased demand for oil, in particular...

Kodiak to exhibit self-driving truck at Ambarella event in Las Vegas during 2023 Consumer Electronics ShowKodiak Equips Autonomous Trucks With Ambarella AI System-on-Chip Kodiak is integrating Ambarella’s CV2AQ AI perception system-on-chip (SoC) into its self-driving trucks for all camera data processing.MOUNTAIN VIEW, Calif. and SANTA CLARA, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Kodiak Robotics, Inc., a leading self-driving trucking company, today announced a partnership with Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, to integrate Ambarella’s CV2AQ AI perception system-on-chip (SoC) into its self-driving trucks for all camera data processing. To kick off the partnership publicly, Kodiak will exhibit one of its self-driving trucks at Ambarella’s demo event in Las Vegas during the 2023 Consumer Electronics...

Noerresundby, Denmark, 4 January 2023Announcement no. 01/2023Enclosed please find the notice to convening the Annual General Meeting of RTX to be held on Thursday 26 January 2023 at 3.00 pm at the Company’s address: Stroemmen 6, Noerresundby. Best regards,RTX A/S Peter Røpke                                                                 CEO Questions and further information: Peter Røpke, CEO, tel. +45 96 32 23 00Please visit RTX’s website at: www.rtx.dkAttachmentRTX CA No 01-2023 – 04.01.2023 – Notice of AGM with agenda and complete proposals